medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2014, Number 609

<< Back Next >>

Rev Med Cos Cen 2014; 71 (609)

Purpura de Henoch-Schönlein en pediatría: Panorama fisiopatológico, clínico y terapéutico

Alonso RJ

Language: Spanish
References: 26
Page: 99-102
PDF size: 163.97 Kb.


ABSTRACT

Henoch Schönlein purpura (HSP) is the leading type of systemic vasculitis in the world. It attacks the small vessels and it manifests itself most commonly in the skin, gastrointestinal tract, joints and kidneys. The course is benign and self-limited. The prognostic of HSP is linked directly to the extent of the renal involvement. The therapy consists of oral corticosteroids; however there are discrepancies between authors on its effectiveness.


REFERENCES

  1. A. M. Huber, J. King, P. McLaine, T. Klassen and M. Pothos. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura. BMC Medicine 2004:1.

  2. A. Nickavar, M. Mehrazma, A. Lahouti. Clinicopathologic Correlations in Henoch-Schonlein Nephritis. IJKD 2012;6:437-401.

  3. Baselga E, Drolet B, Esterly N. Purpura in infants and children. J Am Acad Dermatol. 1997; 37:673- 705.

  4. B. V. Reamy, P. M. Williams, T. J. Lindsay. Henoch-Schönlein Purpura. American Family Physician 2009; 80:697-704.

  5. C. S. Alfredo, N. A. Nunes, C. A. Len, C. M. Barbosa, M. R. A. Terreri, M. Odete E. Hilário. Henoch-Schönlein purpura: recurrence and chronicity. J Pediatr. 2007; 83:177-180.

  6. Chen O, Zhu XB, Ren P, Wang YB, Sun RP, Wei DE. Henoch Schönlein Purpura in children: clinical analysis of 120 cases. African Health Sciences 2013; 13: 94 – 99.

  7. D. B. Nebreda, F. C. Vicente, A. A. Muntañola. Púrpura de Schönlein- Henoch. Piel. 2006; 21:484-92.

  8. Dolezalova P, Telekesova P, Nemcova D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol 2004; 31:2295–9.

  9. E J Tizard, M J J Hamilton-Ayres. Henoch–Schönlein purpura. Arch Dis Child Educ Pract Ed 2008; 93:1–8.

  10. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69:798–806.

  11. G. D, S. F. Púrpura de Schönlein Henoch. Arch Argent Pediatr. 2001; 99:168-170.

  12. H Narchi. Risk of long term renal impairment and duration of follow up recommended for Henoch- Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005; 90:916–920.

  13. Hugh J. McCarthy & E. Jane Tizard. Clinical practice: Diagnosis and management of Henoch–Schönlein purpura. Eur J Pediatr 2010; 169:643–650

  14. Jahed M. Hamdan, Mousa A. Barkawi. Henoch Schönlein Purpura in Children: Influence of age on the incidence of nephritis and arthritis. Saudi Med J 2008; 29:549-552

  15. J. Davin. Henoch-Schönlein Purpura Nephritis: Pathophysiology, Treatment, and Future Strategy. Clin J Am Soc Nephrol 2011;6: 679–689.

  16. J. Aalberse, K. Dolman, G. Ramnath, R. Rodrigues Pereira, J. Claude Davin. Henoch–Schönlein purpura in children: an epidemiological study among Dutch paediatricians on incidence and diagnostic criteria. Ann Rheum Dis 2007; 66:1648– 1650.

  17. J. J. de Almeida, L. M. A. Campos, L. B. Paim, C. Leone, V. Hermínia K. Koch, C. Artur A. Silva. Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors. J Pediatr (Rio J). 2007;83:259-266.

  18. J. Ronkainen, O. Koskimies, M. Ala-Houhala, M. Antikainen, J. Merenmies, J. Rajantie, T. Örmala, J. Turtinen and M. Nuutinen. J Pediatr 2006;149:241-7.

  19. L. Ángeles, R. Ballona. Púrpura de Henoch-Schönlein: epidemiología, clínica y seguimiento por cinco años en pacientes hospitalizados en el Instituto Especializado de Salud del Niño, 1995-1999. Folia dermatol. Peru 2007; 18: 111-117.

  20. L. Watson, A. R. W. Richardson, R. C. L. Holt, C. A. Jones, M. W. Beresford. Henoch Schonlein Purpura. A 5-Year Review and Proposed Pathway. PLoS ONE 2012; 7: e29512 .

  21. L. B. Gámez González, A. Rodríguez Lozano, F. Rivas Larrauri, M.Yamazaki-Nakashimada. Enfermedad de Kawasaki y púrpura de Henoch-Schönlein: vasculitis frecuentes en una asociación 102 REVISTA MEDICA DE COSTA RICA Y CENTROAMERICA infrecuente. Revista Alergia México 2012; 59:37-40.

  22. M.A. Gonzalez-Gay, M.C. Calviño, M.E. Vazquez-Lopez, C. Garcia- Porrua, J.L. Fernandez-Iglesias,T. Dierssen, J. Llorca. Implications of URTI and drugs in the clinical spectrum of Henoch-Schönlein purpura in children. Clinical and Experimental Rheumatology 2004; 22: 781-784.

  23. P. F. Weiss, , J. A. Feinstein, , X. Luan, MS, J. M. Burnham, C. Feudtner. Effects of Corticosteroid on Henoch-Schönlein Purpura: A Systematic Review. Pediatrics. 2007 November; 120(5): 1079–1087.

  24. R. Coppo, G. Mazzucco, L. Cagnoli1, A. Lupo, F. P. Schena. Long-term prognosis of Henoch– Schönlein nephritis in adults and children. Nephrol Dial Transplant 1997; 12: 2277–2283.

  25. Yang YH, Hung CF, Hsu CR, Wang LC, Chuang YH, Lin YT, et al. A nationwide survey on epidemiological characteristics of childhood Henoch–Schönlein purpura in Taiwan.Rheumatology 2005;44:618-622.

  26. Yilmaz Tabel, Filiz Callak Inanc, Derya Gumus Dogan, Ahmet Taner Elmas. Clinical Features of Children With Henoch-Schonlein Purpura: Risk Factors Associated With Renal Involvement. IJKD 2012:269-74.




2020     |     www.medigraphic.com